trending Market Intelligence /marketintelligence/en/news-insights/trending/yxZiCiBuhy5RvMHh6oc8mA2 content esgSubNav
In This List

Exelixis plans US drug application on positive cancer treatment results

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Exelixis plans US drug application on positive cancer treatment results

Exelixis Inc. said Oct. 10 its cabozantinib drug performed better against sunitinib in treating advanced kidney cancer, prompting the company to plan an application for the treatment in the U.S.

Results from randomized phase two trial with patients suffering from previously untreated advanced renal cell carcinoma showed cabozantinib decreasing rate of disease progression or death by 31% when compared to sunitinib, which is marketed by Pfizer Inc

Exelixis and partner Ipsen will jointly host a live webcast at 1 p.m. ET on Oct. 10 to discuss the study and its data.